Tagged with R

clinical trials The global CEO of Arianne, who herself happens to be American-Algerian, outlines why, in an era of clinical research globalisation, the country has all the right fundamentals in place to establish itself as a leader in conducting clinical trials and how the Algerian genetic code is well suited for testing Western orientated pharmaceutical…

clinical trials LSK Global PS CEO Young-Jack Lee discusses the influence of global CROs on the quality of Korean research, and outlines his own strategy for competing in the marketplace and growth outside of Korea.   When we met you in 2008, you were positive about the growth of Korean CROs and…

Sanofi Sanofi’s Korean affiliate is the fifth largest recipient of clinical trial investments after the United States, France, Germany and the United Kingdom. Kay Bae, general manager, discusses the benefits of clinical testing in Korea and why ‘open innovation’ is important for progress and development.   You became general manager of…

partnering The Korean Institute of Toxicology (KIT) is a government-funded research institute that evaluates the safety of medicine, bio-related products and chemicals. PharmaBoardroom talks to Lee Sang-Joon, President of KIT about his current operations and his vision for the future.     Can you discuss the role that KIT plays today…

partnering Korea possesses enormous potential to become an exporter of futuristic health systems in the near future, and has already started the process. Kim Han-Joong, chairman of the strategy committee at CHA Health Systems, outlines Korea’s strengths in healthcare and its forward-looking vision for the future.   You became chairman of…

innovation The Korea Drug Research Association (KDRA) was founded in 1986 to represent local pharmaceutical companies in their mission for global drug development. Kang-Choo Lee, president of KDRA, discusses the current scenario for local companies and outlines his ambitions for making Korea a global hub for innovation.   Since we met…

clinical trials The president of Astellas Korea offers his perspectives on Korea as a base for primary and clinical research, and the company’s recent partnerships in the country.   You became president of Astellas Korea in 2011, following a long career at this affiliate. What were the biggest objectives you had when…

clinical trials The head researcher at P&K Skin Research Center discusses the potential of South Korea as a clinical trial hub, and the company’s current expansion plans.   What differentiates P&K Skin from its competitors, and what are the key characteristics of the Korean market that attract foreign patients and companies? We…

MSD Don Hyun, president of MSD Korea, shares his vision to bring Korean pharmaceutical companies to the global stage and to bring a locally produced drug to blockbuster status in the coming years.   2014 represents MSD’s 20th anniversary in Korea. How did the affiliate commemorate the occasion? In the current…

hospital The director of the Hanyang University Hospital for Rheumatic Diseases (HUHRD), discusses Korea’s leading role in developing biosimilars as well as the hospital’s efforts to curb chronic diseases.   As a leading expert in rheumatism, what have been some of the main developments in this particular area of study? Rheumatologic…

clinical trials The Korea National Enterprise for Clinical Trials (KoNECT) was established in 2007 by the Korean government to meet the increasing demand for local clinical trials and strengthen the country’s clinical research network. Deborah Chee, president of KoNECT, explains the organization’s ambition to become a world leader in clinical trials.   When…

servier The country manager of a multinational keen to ramp up its activities in the local market discusses the strategic importance of the Algerian pharmaceutical sector from both a regional and global perspective and sheds light on the sorts of market entry strategies that can be adopted. What are your priorities for Servier…